Drug interaction in psycho-oncology: Antidepressants and antineoplastics

Pharmacology

Volumn 88, Issue 5-6, 2011, Pages 333-339

  Miguel, C ^a   Albuquerque, E ^b  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b Instituto Portugues de Oncologia Francisco Gentil Centro Regional de Oncologia de Coimbra SA   (Portugal)

Author keywords

Antidepressants; Antineoplastic drugs; Drug interactions

Indexed keywords

ALTRETAMINE; AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ANTINEOPLASTIC AGENT; CARBOPLATIN; CHLORMETHINE; CISPLATIN; CITALOPRAM; CYTOCHROME P450; DULOXETINE; ENDOXIFEN; ESCITALOPRAM; ESTRAMUSTINE; FLUOROURACIL; FLUOXETINE; FLUVOXAMINE; GEMCITABINE; IMATINIB; LOMUSTINE; MELPHALAN; MERCAPTOPURINE; MILNACIPRAN; MIRTAZAPINE; PAROXETINE; SERTRALINE; TAMOXIFEN; TEMOZOLOMIDE; TIOGUANINE; UNINDEXED DRUG; VENLAFAXINE;

BREAST CANCER; CANCER PATIENT; CHEMOTHERAPY INDUCED EMESIS; DEPRESSION; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; DRUG SAFETY; DRUG TRANSFORMATION; ENZYME INHIBITION; ENZYME SUBSTRATE; HUMAN; NAUSEA; NEOPLASM; NEUTROPENIA; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; WEIGHT GAIN;

ANIMALS; ANTIDEPRESSIVE AGENTS; ANTINEOPLASTIC AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; DEPRESSIVE DISORDER; DRUG INTERACTIONS; HUMANS; NEOPLASMS;

EID: 82055175104     PISSN: 00317012     EISSN: 14230313     Source Type: Journal    
DOI: 10.1159/000334738     Document Type: Review

References (36)

1. Pasquini M, Biondi M, Costantini A, Cairoli F, Ferrarese G, Picardi A, Sternberg C: Detection and treatment of depressive and anxiety disorders among cancer patients: Feasibility and preliminar findings from a Liason Service in an Oncology division. Depress Anxiety 2006; 23: 441-448. (Pubitemid 44757154)
2. Grassi L, Nanni MG, Uchitomi Y, Riba M, Kissane DW, Maj M, Sartorius N: Pharmacotherapy of depression in people with cancer; in Kissane DW, Maj M, Sartorius N (eds): Depression and Cancer. Chichester, Wiley, 2010.
3. Carvalho VA, Macieira RC, Liberato RP, Veit MT, Kovács MJ, Gomes MJB, et al: Temas em psico-oncologia. São Paulo, Summus Editorial, 2008.
4. Massie MJ: Prevalence of depression in patients with cancer. J Natl Cancer Inst Monogr 2004; 32: 57-71.
5. Grassi L, Holland JC, Johansen C, Koch U, Fawzy F: Psychiatric concomitants of cancer, screening procedures, and training of health care professionals in oncology: The paradigms of psycho-oncology in the psychiatry field; in Christodoulou GN (ed): Advances in Psychiatry. Athens, Beta Publishing Athens, 2005.
6. Hjerl K, Andersen EW, Keiding N, Mouridsen HT, Mortensen PB, Jorgensen T: Depression as a prognostic factor for breast cancer mortality. Psychosomatics 2003; 44: 24-33.
7. Stommel M, Given BA, Given CW: Depression and functional status as predictors of death among cancer patients. Cancer 2002; 94: 2719-2727. (Pubitemid 34478089)
8. Okamura M, Akizuki N, Nakano T, Shimizu K, Ito T, Akechi T, Uchitomi Y: Clinical experience of the use of a pharmacological treatment algorithm for major depressive disorder in patients with advanced cancer. Psychooncology 2008; 17: 154-160. (Pubitemid 351279866)
9. Rayner L, Rayner L, Price A, Hotopf M, Higginson IJ: The management of depression in palliative care. Eur J Cancer Care 2011; 47: 702-712.
10. Stiefel FC, Komblith AB, Holland JC: Changes in prescription patterns of psychotropic drugs for cancer patients during a 10-year period. Cancer 1990; 65: 1048-1053. (Pubitemid 20063514)
11. Rodin G, Katz M, Lloyd N, Green E, Mackay JA, Wong RK: Treatment of depression in cancer patients. Curr Oncol 2007; 14: 180-188.
12. Kalash GR: Psychotropic drug metabolism in cancer patients: Clinical aspects of management of potential drug interactions. Psychooncology 1998; 7: 307-320.
13. Yap KY, Ho YX, Chui WK, Chan A: Harnessing the internet cloud for managing drug interactions with chemotherapy regimens in patients with cancer suffering from depression. Acta Oncol 2010; 49: 1235-1245.
14. Ciraulo DA, Shader RI, Greenblatt DJ, Creelman WL: Drug Interactions in Psychiatry, ed 3. Philadelphia, Lippincott Williams &Wilkins, 2006.
15. Tatro DS: Drug Interactions Facts: The Authority on Drug Interactions. St Louis, Facts &Comparations, 2008.
16. Richelson E: Pharmacokinetic drug interactions of new antidepressants: A review of the effects on metabolism of other drugs. Mayo Clin Proc 1997; 72: 835-847. (Pubitemid 27382924)
17. Haddad A, Davis M, Lagman R: The pharmacological importance of cytochrome CYP3A4 in palliation of symptoms: Review and recommendations for avoiding adverse drug interactions. Support Care Cancer 2007; 15: 251-257. (Pubitemid 46295205)
18. Kelly MC, Juurlink DN, Gomes T, Duon- Hua M, Pritchard KI, Austin PC, Paszat LF: Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: A population cohort study. BMJ 2010; 340:c693.
19. Desmarais JE, Looper KJ: Interactions between tamoxifen and antidepressants via cytochrome P450 2D6. J Clin Psychiatry 2009; 70: 1688-1697.
20. Barreiro RJ, Siva JFM, Fraga CA: Noções básicas do metabolismo de fármacos. Rev Química Nova 1996; 19: 441-451.
21. Scripture DC, Figg WD: Drug Interactions in Cancer Therapy: Pharmacokinetic Interactions: Metabolism. 2006. http:// www.medscape.com/ viewarticle/540883-4 (accessed May 9, 2011).
22. Evans WE, McLeod HL: Pharmacogenomics - Drug disposition, drug targets, and side effects. N Engl J Med 2003; 348: 538-549. (Pubitemid 36159890)
23. Schroth W, Antoniadou L, Fritz P, Schwab M, Muerdter T, Zanger UM, et al: Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol 2007; 25: 5187-5193. (Pubitemid 350232249)
24. Schroth W, Goetz MP, Hamann U, Fasching PA, Schmidt M, Winter S, et al: Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 2009; 302: 1429-1436.
25. Kiyotani K, Mushiroda T, Sasa M, Bando Y, Sumitomo I, Hosono N, et al: Impact of CYP2D6 * 10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy. Cancer Sci 2008; 99: 995-999. (Pubitemid 351997603)
26. Xun Y, Sun Y, Yao L, Shi L, Wu Y, Ouyang T, et al: Association between CYP2D6 * 10 genotype and survival of breast cancer patients receiving tamoxifen treatment. Ann Oncol 2008; 19: 1423-1429.
27. Jin Y, Desta Z, Stearns V, Ward B, Ho H, Lee KH, et al: CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 2005; 97: 30-39.
28. Borges S, Desta Z, Li L, Skaar TC, Ward BA, Nguyen A, et al: Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: Implication for optimization of breast cancer treatment. Clin Pharmacol Ther 2006; 80: 61-74. (Pubitemid 43946844)
29. Yue QY, Säwe J: Different effects of inhibitors on the O-And N-demethylation of codeine in human liver microsomes. Eur J Clin Pharmacol 1997; 52: 41-47. (Pubitemid 27168210)
30. Shin JG, Parks JY, Kim MJ, Shon JH, Yoo YR, Cha IJ, et al: Inhibitory effects of tricyclic antidepressants (TCAs) on human cytochrome p450 enzymes in vitro: Mechanism of drug interaction between TCAs and phenytoin. Drug Metab Dispos 2002; 30: 1102-1107.
31. Flockhart DA: Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine. 2007. http://medicine.iupui.edu/ clinpharm/ddis/ table.asp (accessed May 9, 2011).
32. Obach RS, Cox LM, Tremaine LM: Sertraline is metabolized by multiple cytochrome P450 enzymes monoamine oxidases, and glucuronyl transferases in human: An in vitro study. Drug metabolism and disposition. Drug Metab Dispos 2005; 33: 262-270. (Pubitemid 40216594)
33. Kazuhisa T, Kazuyuki T, Katsuya O, Satoko K, Noriaki S, Yasufumi S: Examination of drug-drug interaction of milnacipran hydrochloride in the presence of human P-450. Iyakuhin Kenkyu 2000; 31: 659-667.
34. Puozzo C, Lens S, Reh C, Michaelis K, Rosillon D, Deroubais X, et al: Lack of interaction of milnacipran with the cytochrome P450 isoenzymes frequently involved in the metabolism of antidepressants. Clin Pharmacokinet 2005; 44: 977-988. (Pubitemid 41252846)
35. Savella (Milnacipran Hydrochloride) - Drug Interactions, Contraindications, Overdosage. 2009. http://www.druglib.com/druginfo/ savella/interactions-overdosage-contraindications (accessed May 9, 2011).
36. Tony A, Tseng A: Potential Interactions between Antineoplastics and Antiretrovirals. 2011. www.hivclinic.ca/main/drugs-interact-files/Chemo-int.pdf (accessed May 9, 2011).